PE20170911A1 - Capsulas blandas de calcifediol - Google Patents
Capsulas blandas de calcifediolInfo
- Publication number
- PE20170911A1 PE20170911A1 PE2017000841A PE2017000841A PE20170911A1 PE 20170911 A1 PE20170911 A1 PE 20170911A1 PE 2017000841 A PE2017000841 A PE 2017000841A PE 2017000841 A PE2017000841 A PE 2017000841A PE 20170911 A1 PE20170911 A1 PE 20170911A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- calcifediol
- soft capsule
- soft
- capsules
- Prior art date
Links
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 title abstract 2
- 235000021318 Calcifediol Nutrition 0.000 title abstract 2
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 title abstract 2
- 229960004361 calcifediol Drugs 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000007901 soft capsule Substances 0.000 abstract 3
- KFZMGEQAYNKOFK-YZRHJBSPSA-N (214C)propan-2-ol Chemical compound [14CH](C)(C)O KFZMGEQAYNKOFK-YZRHJBSPSA-N 0.000 abstract 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 208000013038 Hypocalcemia Diseases 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 abstract 1
- 238000005115 demineralization Methods 0.000 abstract 1
- 230000002328 demineralizing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000000705 hypocalcaemia Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paints Or Removers (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Lubricants (AREA)
- Carbon And Carbon Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170911A1 true PE20170911A1 (es) | 2017-07-12 |
Family
ID=52462260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000841A PE20170911A1 (es) | 2015-02-06 | 2016-02-05 | Capsulas blandas de calcifediol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10525018B2 (enExample) |
| EP (3) | EP3053598A1 (enExample) |
| JP (2) | JP6427270B2 (enExample) |
| KR (1) | KR101971384B1 (enExample) |
| CN (2) | CN106999441B (enExample) |
| AU (1) | AU2016214336B2 (enExample) |
| BR (1) | BR112017010657B1 (enExample) |
| CA (1) | CA2967170C (enExample) |
| CL (1) | CL2017001335A1 (enExample) |
| CO (1) | CO2017004545A2 (enExample) |
| CY (1) | CY1122976T1 (enExample) |
| DK (2) | DK3689380T3 (enExample) |
| EA (1) | EA034821B1 (enExample) |
| ES (2) | ES2738642T3 (enExample) |
| HR (1) | HRP20200859T1 (enExample) |
| HU (1) | HUE050133T2 (enExample) |
| LT (1) | LT3204047T (enExample) |
| MA (2) | MA41058B1 (enExample) |
| MD (1) | MD3204047T2 (enExample) |
| ME (1) | ME03739B (enExample) |
| MX (1) | MX367999B (enExample) |
| MY (2) | MY189432A (enExample) |
| PE (1) | PE20170911A1 (enExample) |
| PH (1) | PH12017501350A1 (enExample) |
| PL (1) | PL3204047T3 (enExample) |
| PT (1) | PT3204047T (enExample) |
| RS (2) | RS60467B1 (enExample) |
| SI (1) | SI3204047T1 (enExample) |
| SM (1) | SMT202000278T1 (enExample) |
| WO (1) | WO2016124724A1 (enExample) |
| ZA (1) | ZA201703444B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
| DE202019005769U1 (de) | 2018-08-31 | 2022-01-13 | Eirgen Pharma Ltd. | Pädiatrische Darreichungsformen von Vitamin D und Verwendung |
| CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| US20220339167A1 (en) * | 2019-08-22 | 2022-10-27 | Industrial Technologies & Biotechnologies | Hormone d (vitamin d) and its derivatives for the treatment and prevention of cancer |
| CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
| WO2022103638A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
| CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
| CN116350598A (zh) * | 2021-12-28 | 2023-06-30 | 人福普克药业（武汉）有限公司 | 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法 |
| CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
| AU2023397554A1 (en) * | 2022-12-14 | 2025-06-12 | R.P. Scherer Technologies, Llc | Softgel capsules and a method for preparing the softgel capsules |
| CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药（青岛）有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532126A (en) * | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| AU6866900A (en) * | 1999-08-31 | 2001-03-26 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
| US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| EA008072B1 (ru) | 2001-12-03 | 2007-02-27 | Новацея, Инк. | Фармацевтические составы, содержащие соединения активного витамина d |
| US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| AU2003230191A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| EP1494683A1 (en) | 2002-04-05 | 2005-01-12 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| SG110107A1 (en) | 2003-09-24 | 2005-04-28 | Bioxell Spa | Compound and use in treatment |
| US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
| US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| CA2570649A1 (en) | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| EP1928471A2 (en) | 2005-09-26 | 2008-06-11 | Novacea, Inc. | Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds |
| US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
| WO2008097646A1 (en) * | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
| DK2148661T3 (da) * | 2007-04-25 | 2013-03-25 | Cytochroma Inc | Orale præparater med kontrolleret afgivelse omfattende vitamin D-forbindelse og voksagtig bærer |
| EP2148684B1 (en) | 2007-04-25 | 2013-01-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| CA2731382C (en) | 2008-07-24 | 2020-04-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
| JP5723287B2 (ja) | 2008-12-15 | 2015-05-27 | バナー ライフ サイエンシズ エルエルシー | 非水溶性活性薬剤の放出および吸収を増強するための方法 |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en not_active Ceased
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 HR HRP20200859TT patent/HRP20200859T1/hr unknown
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko not_active Ceased
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 SM SM20200278T patent/SMT202000278T1/it unknown
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 MY MYPI2021001039A patent/MY199862A/en unknown
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170911A1 (es) | Capsulas blandas de calcifediol | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2020012041A (es) | Formulacion farmaceutica. | |
| CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| AR102372A1 (es) | Composición que comprende una mezcla de extractos vegetales o una mezcla de moléculas contenidas en dichos vegetales, y su utilización para actuar sobre el metabolismo glucídico y/o lipídico | |
| CO2019010505A2 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| PE20170188A1 (es) | Formulaciones y metodos de tratamiento con queratina | |
| SV2010003777A (es) | Compuestos organicos | |
| MX2016006896A (es) | Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica. | |
| AR100306A1 (es) | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia | |
| CO2018001628A2 (es) | Composiciones y formulaciones antimicrobianas | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| MX2015009195A (es) | Particulas secadas por rociado estables en almacenamiento. | |
| MX2024010721A (es) | Formulaciones topicas que contienen ciclosporina y usos de las mismas. | |
| CO2019010578A2 (es) | Derivados de fenilo como moduladores del receptor de pge2 | |
| PE20142043A1 (es) | Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| PE20141011A1 (es) | Formulacion farmaceutica que comprende inositol | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CL2016002363A1 (es) | Feromona tranquilizadora para gatos. | |
| PE20241347A1 (es) | MODULAR LA EXPRESION DE APOLIPOPROTEINA (a) | |
| MX2017014092A (es) | Metodo para obtener una biomasa de una microalga de la especie tetraselmis chuii enriquecida en superoxido dismutasa (sod). | |
| CR20120134A (es) | Derivados de pirazol que modulan la estearoil-coa-desaturasa | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. |